Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

• Status: Recruiting
• Trial end date: 2030-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Alverine; Ethosuximide; Mebeverine; Pentoxifylline

Criteria

Inclusion Criteria:

• • Age ≥ 18 years,

• Man and Women, Negative pregnancy test and effective contraception,

• IBS defined by the Rome criteria IV

• During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.

• IBS Treatment stable for 1 month

Exclusion Criteria:

• • Breastfeeding

• Diabetic patients

• Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min)

• Addiction to alcohol and / or drugs,

• Antiepileptic drugs taken (epilepsy or chronic pain)

• Chronic pain of greater intensity than that related to IBS,

• Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.

• History or current severe depression (hospitalization, long-term antidepressant treatment)

• Psychotic disorders,